Abbott to Conduct BE Study for Carbimazole 15 mg, Trial Waiver Granted In India
Advertisement
New Delhi: Abbott Healthcare Pvt. Ltd has received the green signal from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) to conduct a bioequivalence (BE) study for its Carbimazole Tablets I.P. 15 mg, while also securing a clinical trial waiver for the formulation.
The decision was taken during the SEC (Endocrinology & Metabolism) meeting held on 24th July 2025, where the firm presented its proposal for grant of permission to manufacture and market two dosage strengths: Carbimazole Tablets I.P. 2.5 mg and 15 mg.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.